donor age – Medxy AI

Hematology-Oncology news Transplantation

Posttransplant Cyclophosphamide Appears to Neutralize the Adverse Effect of Older Unrelated Donor Age on Survival After Allogeneic HCT

By MedXY 11/12/2025

A CIBMTR registry cohort (n=10,025) found donor age predicted worse overall survival with conventional calcineurin inhibitor prophylaxis but not with posttransplant cyclophosphamide (PTCy); attenuation was driven by reduced nonrelapse mortality in PTCy recipients.